Acasti Pharma Inc. Retains Lytham Partners to Lead Strategic Investor Relations and Shareholder Communication ProgramPRNewsWire • 05/23/22
Acasti Pharma Announces Positive Results for Pharmacokinetic Bridging Study, With Intravenous GTX-104 Meeting All EndpointsGlobeNewsWire • 05/18/22
Update: Acasti Pharma CEO to Present at Microcap Rodeo's Spring into Action Best Ideas Virtual Conference on May 18thAccesswire • 05/16/22
Acasti Pharma CEO to Present at Microcap Rodeo's Spring into Action Best Ideas Virtual Conference on May 16thAccesswire • 05/12/22
Acasti Pharma to Present at the B. Riley Securities' 2022 Virtual Neuro & Ophthalmology Conference on April 28thGlobeNewsWire • 04/25/22
Acasti Pharma Appoints Healthcare Industry Leader Michael L. Derby to its Board of DirectorsGlobeNewsWire • 03/25/22
Acasti Pharma Announces Patents for GTX-104 in Europe, GTX-102 in the U.S. and GTX-101 in JapanGlobeNewsWire • 03/22/22
Acasti Pharma CEO to Present at the 32nd Annual Oppenheimer Healthcare Conference on March 16thGlobeNewsWire • 03/09/22
Acasti Pharma Inc. (ACST) CEO Jan D'Alvise on Q3 2021 Results - Earnings Call TranscriptSeeking Alpha • 02/14/22
Acasti Pharma Schedules Third Quarter Fiscal 2022 Business Update Conference CallGlobeNewsWire • 02/07/22
Acasti Pharma's Hemorrhage Candidate Shows Encouraging PK Profile In Healthy VolunteersBenzinga • 12/02/21
Acasti Pharma Announces Interim Data Meets All Primary Endpoints for Pivotal PK Study for GTX-104GlobeNewsWire • 12/02/21
Acasti Pharma CEO to Participate in the Benzinga All Access Event on December 2ndGlobeNewsWire • 11/24/21